Healthcare Professionals
Please log in for special information and services
New here?
sign up for personal account

Product Details

Adasuve® is indicated for the rapid control of mild-to-moderate agitation (increased, unproductive physical activity coupled with internal tension) in adult patients with schizophrenia or biopolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. 

Adasuve® 9.1 mg inhalation powder, pre-dispensed.

Ferrer Internacional, S.A. is the MA-Holder and AOP Orphan has the distribution right.

Patient Information Leaflet Adasuve® in German   
 

Drug Facts

Active ingredient

Loxapin